Singular Genomics Systems (NASDAQ:OMIC) Posts Quarterly Earnings Results, Beats Estimates By $1.33 EPS

Singular Genomics Systems (NASDAQ:OMIC) posted its quarterly earnings results on Tuesday. The company reported ($6.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($8.05) by $1.33, Zacks reports. Singular Genomics Systems had a negative return on equity of 54.70% and a negative net margin of 3,237.89%. The business had revenue of $0.41 million during the quarter, compared to analyst estimates of $0.74 million.

Singular Genomics Systems Stock Down 1.9 %

Shares of OMIC opened at $22.53 on Thursday. Singular Genomics Systems has a 52-week low of $5.34 and a 52-week high of $23.41. The company has a quick ratio of 8.04, a current ratio of 8.77 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $14.99 and a two-hundred day simple moving average of $11.25. The company has a market capitalization of $56.33 million, a PE ratio of -0.64 and a beta of 1.51.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.